Government of Saskatchewan
Ministry of Health

Saskatchewan Immunization Manual Amendments December 2016

Instructions: Please remove and discard the corresponding pages in each chapter section and insert the amended pages as noted below in each corresponding chapter section dated December 2016.

Chapter 8 Administration of Biological Products

- Table of content first page (April 2014) updated.
- P. 1 section 1.1.1 General Screening questions (August 2012)
  - New screening questions added:
    1. Has the mother taken any immune-suppressing drugs during her pregnancy with this child?
    2. Has the mother taken any immune-suppressing drugs while breastfeeding this child?
- P. 2 Section 1.3.1 Pre-Preparation: Pre-Loading of Syringes (October 2013)
  - Directions removed as not a recommended practice.
  - New statement: Pre-preparation of prefilled syringes and pre-loading of syringes with biological products that come in vial or ampoule presentations is discouraged because of the uncertainty of product stability in syringes, risk of contamination, increased potential for administration errors, and biological product wastage.
- P. 3 Section 1.3.2 Preparation Instructions (August 2012)
  - #1 instruction updated: 10 Rights of medication prepare products have been added.
- P. 4 Section 1.3.3 Vials and section 1.3.4 Vaccine with Diluents (August 2012)
  - New statement added to 1.3.3 #5: Do not insert blunt needles with or without a filter into vials because of coring risk.
  - New statement added to 1.3.4 #2: Do not insert blunt needles with or without a filter into vials because of coring risk
- P. 5 section 1.3.6 Multidose Vials (April 2014)
  - Section fully revised.
- P. 7 Section 1.5 Publicly Funded Immunizations Following Non-Conforming Situations (June 2014)
  - 4-Day Grace Period Principles - revised content.
- P. 8 (August 2012)
  - Sections 1.5.1 to 1.5.5 added to this page.
- P. 19 (Section 2.7) Table 2 (April 2014)
  - Direct copy of TB Skin Test Interpretations from Canadian Tuberculosis Standards, 7th Edition 2013.

Chapter 10 Biological Products

- HAHB (September 2016)
  - High risk population added on footnote #2 was left off previous update.
- Engerix B (Nov. 2015) and Recombivax HB (April 2015)
  - New footnote #5 added: Infant must be at least 24 weeks of age to receive 3rd dose.
- FluLaval tetra and Fluzone Quadrivalent (both September 2016)
  - Under Contraindications section for both vaccines, bullet #2 now states: History of anaphylactic reaction to any component of any influenza vaccine.
- Pneum-P-23 (page 1 September 2016)
  - Alcoholism added as noted on Pneu-P-23 fact sheet.
- IMOVAX® Polio (May 2016)
  - #1 Dose 3 now states: Dose 3: 0.5 mL SC given 8 weeks after dose 2.
  - New statement under 2 & 3: NOTE: At minimum, one dose must be given at or after 4 years of age.

Government of Saskatchewan
Ministry of Health

Saskatchewan Immunization Manual Amendments December 2016

Chapter 14 Appendices

- p. 21 (September 2016)
  - Caring for Your Child's Fever date updated.